ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.20% to 7206.90.
The Resmed CDI (ASX: RMD) share price was crushed after its Q4 2023 financial results. Is Resmed’s share price an allergic reaction to Ozempic, or something else?
The Cochlear Limited (ASX: COH) share price bounced dramatically higher this week following a bumper report. But is the Cochlear share price looking a little expensive? Stock Doctor’s Daniel Ortisi weighs in.
S&P/ASX 200 (ASX:XJO) managed a 0.2% gain on Friday, overcoming weakness in healthcare. Karoon Energy Ltd (ASX:KAR) share price rose 4.2%.
ResMed CDI (ASX: RMD) shares are trading down about -11% in early trade to ~$30 per share after its 4Q23 result came in below consensus expectations.
The Resmed CDI (ASX:RMD) share price bounced 6.5% higher today following the release of its Q3 results. Resmed and CSL Limited (ASX:CSL) seem good value relative to Cochlear Limited (ASX:COH).
Resmed CDI (ASX:RMD) shares and the Monash IVF Group Ltd (ASX:MVF) share price look very tempting at these prices, writes Seneca’s Luke Laretive.
LIVE ASX reporting season coverage is on The Australian Investors Podcast. Today Owen Rask & Drew Meredith cover Commonwealth Bank of Australia (ASX:CBA), AMP Limited (ASX:AMP), ResMed Inc (ASX:RMD) and more.
On Wednesday, the Australian share market, or S&P/ASX 200 (INDEXASX: XJO) and All Ordinaries (ASX: XAO), hits its lowest level since 2020. Overnight, however, a firm 0.75% increase in US interest rates allowed the US stock market to bounce 1.5%.
